Given that SMARCA4 is also inactivated in a variety of other cancer types6, this common druggable vulnerability shared by SCCOHT and NSCLC may also be conserved in other SMARCA4-deficient tumors. Here, SMARCA4 is linked to non-small cell lung carcinoma.